US equities |
AAPL $332.30 ▼-1.78% MU $860.64 ▲+3.25% NVDA $208.25 ▲+3.06% AMD $489.22 ▲+4.79% SNDK $1,128.50 ▲+4.97% ORCL $124.55 ▲+4.47% PLTR $170.18 ▼-4.58% SPCX $140.72 ▲+3.19%
FinancialContent

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

19.79 +0.02 (+0.13%)
Delayed Quote Updated: 10:12 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 7 Next >
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Which stocks are gapping on Friday? ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
News headline image
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
Top movers in Friday's session ↗
Via Chartmill
Which stocks are moving on Thursday? ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Leadership Changes
From Silence Therapeutics plc
Via Business Wire
News headline image
Bausch Health’s Slow Rebuild Faces New Scrutiny After Lombard Odier Cuts Its Stake ↗
Bausch Health’s valuation suggests potential, but the stake cut shows how far the company still has to go to earn back full investor confidence. 
Via The Motley Fool
News headline image
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
From Silence Therapeutics plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Silence Therapeutics to Participate in September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence (SLN) Q2 Revenue Drops 71% ↗
Via The Motley Fool
News headline image
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
From Silence Therapeutics plc
Via Business Wire
News headline image
These stocks are moving in today's pre-market session ↗
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Silence Therapeutics plc
Via Business Wire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15 ↗
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 Next >